PMID- 31022059
OWN - NLM
STAT- MEDLINE
DCOM- 20190502
LR  - 20190502
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 29
IP  - 3
DP  - 2019 Jun
TI  - Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a
      patient with cutaneous melanoma and ocular metastases.
PG  - 345-347
LID - 10.1097/CMR.0000000000000591 [doi]
FAU - Fernandez-Diaz, Amaya B
AU  - Fernandez-Diaz AB
AD  - Medical Onoclogy Service.
FAU - Garcia-Medina, Adrian
AU  - Garcia-Medina A
AD  - Department of Medical Oncology, National Medical Center 'November 20' of the
      Institute of Security and Social Services of State Workers, National Autonomous
      University of Mexico, Mexico City, Mexico.
FAU - Ferrer-Guillen, Blanca
AU  - Ferrer-Guillen B
AD  - Dermatology Service, Consorcio Hospital General Universitario de Valencia,
      Valencia, Spain.
FAU - Berrocal, Alfonso
AU  - Berrocal A
AD  - Medical Onoclogy Service.
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
CON - Melanoma Res. 2018 Aug;28(4):359-362. PMID: 29634634
MH  - Antibodies, Monoclonal
MH  - Humans
MH  - *Immune Privilege
MH  - Immunotherapy
MH  - Ipilimumab
MH  - *Melanoma
MH  - Nivolumab
MH  - *Skin Neoplasms
EDAT- 2019/04/26 06:00
MHDA- 2019/05/03 06:00
CRDT- 2019/04/26 06:00
PHST- 2019/04/26 06:00 [entrez]
PHST- 2019/04/26 06:00 [pubmed]
PHST- 2019/05/03 06:00 [medline]
AID - 10.1097/CMR.0000000000000591 [doi]
AID - 00008390-201906000-00021 [pii]
PST - ppublish
SO  - Melanoma Res. 2019 Jun;29(3):345-347. doi: 10.1097/CMR.0000000000000591.